Module

Insights Into the Pathogenesis, Classification, and Treatment of Myelodysplastic Syndromes

Source: Treatment Challenges in Myelodysplastic Syndromes

Insights Into the Pathogenesis, Classification, and Treatment of Myelodysplastic Syndromes

Faculty:
Alan F. List, MD

CME CREDIT INFORMATION

Release Date: 04/02/08

Expiration Date: 04/01/09

Physicians: maximum of 1.25 AMA PRA Category 1 Credit(s)™

Registered Nurses: 1.2 Nursing CE credits

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe the various classification systems for myelodysplastic syndromes
Discuss data from clinical studies of approved and investigational treatments for myelodysplastic syndromes
Explain the underlying pathogenesis of myelodysplastic syndromes

Topics covered include:

Introduction
Insights Into the Pathogenesis of MDS
Evolving Classification Systems and Prognostic Indices for MDS
Advances in Supportive Care for MDS
Stem Cell Transplantation
Immunomodulatory Treatment of MDS: Lenalidomide
Azacitidine: A First-Generation Hypomethylating Agent for MDS Treatment
Decitabine: A Second-Generation Hypomethylating Agent for MDS Treatment
Immunosuppressive Therapy
Future Directions

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.